FIRST TIME VISITOR? CLICK HERE!

Welcome to AIDS-Drugs-Online.com.

Our website ensures an easy ordering process for affordable HIV/AIDS and PrEP medications, as well as protection of our customers' information. Having an account on our website allows you to place your orders easily, upload your prescriptions safely, view your order history, and even earn discounts.

If you have not ordered from us before:
You can create an account for free by clicking here.

Please take a moment to learn how to order. If you have any trouble, please call us at 1-888-243-7675.

Australia: +61 (2) 90537441 Switzerland: +41 (44) 7982088

We invite you to explore our website and save money on your HIV/AIDS and PrEP medications!


Descovy 200/10mg
30 tablet(s)

Descovy 200/10mg

$924.99 USD
+ shipping and handling
0 Review(s)

Prescription required

Active Ingredient(s): emtricitabine/tenofovir alafenamide
Manufacturer: Gilead Science Inc.
Brand: Yes
Country of origin: Canada
30 tablet(s)
Active Ingredient(s): emtricitabine/tenofovir alafenamide
Manufacturer: Gilead Science Inc.
Brand: Yes
Country of origin: Canada
Knows Names:

DESCOVY is a combination formulation of the Nucleoside and Nucleotide Reverse Transcriptase Inhibitor (NRTI) drugs emtricitabine (200mg) and tenofovir alafenamide (10mg). It is used for the treatment of HIV infection in patients without Hepatitis B virus (HBV) or Hepatitis C virus (HCV) co-infection. Please note that DESCOVY contains tenofovir alafenamide, a newer formulation of the NRTI tenofovir disoproxil fumarate, and differs in various aspects. Tenofovir alafenamide, the version present in DESCOVY, has a reduced side effect profile.

Dosing & Administration

DESCOVY is indicated for the treatment of HIV infection in adults and children weighing at least 25 kg, in combination with other antiretroviral medications. The dose is one tablet once daily with or without food. DESCOVY comes in a film-coated oral tablet.

No dosage adjustments are required in patients with mild to moderate liver dysfunction. No dosage adjustments are required in renal dysfunction, but DESCOVY should not be used if the creatinine clearance is less than 30 mL/min. Dosage instructions are detailed in the product monograph.

Contraindications

DESCOVY is contraindicated in patients with hypersensitivity to the drug.

Side Effects

DESCOVY is associated with reduced bone mineral density (BMD), and with hepatotoxicity (see precautions). Other potential side effects include osteonecrosis, immune reactivation syndrome, nausea, body fat redistribution, and increased cholesterol. A complete list of potential adverse effects is provided in the product monograph.

Precautions

DESCOVY is not indicated for the treatment of HBV infection, and should not be used in HIV patients who are co-infected with HBV of HCV due to increased risk of hepatotoxicity.

All patients who test positive for an HIV infection should be screened for a comorbid HBV infection. Co-infected patients should be started on an antiretroviral regimen targeting both viruses, regardless of CD4 counts or HBV viral loads. Current HIV treatment guidelines outline drug regimens and prescribing considerations.

Current HIV treatment guidelines recommend testing HIV-positive patients for Hepatitis C virus (HCV), and regular ongoing testing for those at high risk. If HIV/HCV co-infection is identified, consideration should be given to treating both infections concurrently.

DESCOVY therapy should be suspended in any patient who develops lactic acidosis or hepatomegaly. Screening and monitoring recommendations are detailed in the product monograph.

DESCOVY has been associated with reduced BMD, so BMD monitoring should be considered in certain patients, as detailed in the product monograph.

Drug Interactions

DESCOVY is associated with a large number of drug-drug and herbal interactions. These are listed in the product monograph.

Pregnancy & Lactation

Highly active retroviral combination treatment should be used in all pregnant women. Effects of DESCOVY in pregnancy are unknown, so current guidelines should be consulted prior to using DESCOVY in pregnant women.  DESCOVY excretion in breast milk is unknown. The CDC recommends that all HIV positive women, treated or untreated, avoid breastfeeding to prevent vertical transmission of the virus.

Overdosage

DESCOVY overdose should be treated by standard supportive measures and close observation. Both active ingredients of DESCOVY are partially dialyzed.

There are no reviews yet
Be the first to review “Descovy 200/10mg”
Star

Reviews are only written by verified customers who have purchased this product.

Related Products

Tenvir EM

Tenvir EM

from $65.00 USD
Abamune-L 600/300 Mg

Abamune-L 600/300 Mg

from $98.00 USD
Viraday

Viraday

from $98.00 USD
Efavir 600mg

Efavir 600mg

from $65.00 USD

Reset your password

Please enter your email below, and we will send you a new password.

Still having trouble signing in?

If you're unable to reset your password, please call Customer Service at 1-888-243-7675.